SEC Form 4 · accession 0001209191-19-015224
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence J. Hineline
Officer — SVP of Finance CFO
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 7:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 27, 2019 | M | 10,000 | $2.74 | A | 25,832 | D | |
| Common Stock | Feb 27, 2019 | M | 400 | $2.74 | A | 26,232 | D | |
| Common Stock | Feb 27, 2019 | S | 1,000 | $15.00 | D | 25,232 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.74 | Feb 27, 2019 | M | 10,000 | D | — | Dec 21, 2020 | Common Stock | 10,000 | 0 | D |
| Stock Option (right to buy)F2 | $2.74 | Feb 27, 2019 | M | 400 | D | — | Jun 10, 2020 | Common Stock | 400 | 9,600 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2018.
- F2All shares underlying this option have vested.